CN112807484A - Polymer hydrogel with slow release function and preparation method thereof - Google Patents
Polymer hydrogel with slow release function and preparation method thereof Download PDFInfo
- Publication number
- CN112807484A CN112807484A CN202110269382.8A CN202110269382A CN112807484A CN 112807484 A CN112807484 A CN 112807484A CN 202110269382 A CN202110269382 A CN 202110269382A CN 112807484 A CN112807484 A CN 112807484A
- Authority
- CN
- China
- Prior art keywords
- percent
- polymer hydrogel
- release function
- phase
- function according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 58
- 229920000642 polymer Polymers 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 claims abstract description 18
- 238000004132 cross linking Methods 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 17
- 239000008367 deionised water Substances 0.000 claims abstract description 16
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 230000003750 conditioning effect Effects 0.000 claims abstract description 15
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 13
- 239000003755 preservative agent Substances 0.000 claims abstract description 13
- 238000010521 absorption reaction Methods 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 239000003623 enhancer Substances 0.000 claims abstract description 9
- 239000011347 resin Substances 0.000 claims abstract description 6
- 229920005989 resin Polymers 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000035515 penetration Effects 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003607 modifier Substances 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 150000002500 ions Chemical class 0.000 claims description 11
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 11
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 11
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 239000011975 tartaric acid Substances 0.000 claims description 8
- 235000002906 tartaric acid Nutrition 0.000 claims description 8
- 239000004408 titanium dioxide Substances 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 5
- 239000005995 Aluminium silicate Substances 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 235000012211 aluminium silicate Nutrition 0.000 claims description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
- 238000004945 emulsification Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 239000002952 polymeric resin Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229960003415 propylparaben Drugs 0.000 claims description 4
- 229920003002 synthetic resin Polymers 0.000 claims description 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- 239000003961 penetration enhancing agent Substances 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims 8
- 239000012730 sustained-release form Substances 0.000 claims 8
- 239000000084 colloidal system Substances 0.000 abstract description 7
- 210000004243 sweat Anatomy 0.000 abstract description 7
- 231100000245 skin permeability Toxicity 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 5
- 229940041616 menthol Drugs 0.000 description 5
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- QUVCFQAHXXKABX-UHFFFAOYSA-K C(CO)(=O)[O-].O[Al+]O Chemical compound C(CO)(=O)[O-].O[Al+]O QUVCFQAHXXKABX-UHFFFAOYSA-K 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000005805 Prunus cerasus Nutrition 0.000 description 1
- 244000207449 Prunus puddum Species 0.000 description 1
- 235000009226 Prunus puddum Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- LVYZJEPLMYTTGH-UHFFFAOYSA-H dialuminum chloride pentahydroxide dihydrate Chemical group [Cl-].[Al+3].[OH-].[OH-].[Al+3].[OH-].[OH-].[OH-].O.O LVYZJEPLMYTTGH-UHFFFAOYSA-H 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 235000020723 lavender extract Nutrition 0.000 description 1
- 229940083980 lavender extract Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000020689 passion flower extract Nutrition 0.000 description 1
- 229940001884 passion flower extract Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000001738 pogostemon cablin oil Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940105022 spearmint extract Drugs 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 235000020767 valerian extract Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a polymer hydrogel with a slow release function and a preparation method thereof, wherein the hydrogel comprises the following components in percentage by mass: 0.01 to 15 percent of active ingredients, 0.01 to 15 percent of ion inhibitors, 0.01 to 1 percent of cross-linking agents, 0.1 to 10 percent of macromolecular resin, 10 to 35 percent of solvents, 0.1 to 15 percent of skin feel conditioning agents, 10 to 55 percent of deionized water, 0.1 to 3 percent of appearance conditioning agents, 0.01 to 1 percent of cross-linking conditioning agents, 0.01 to 1 percent of preservatives and 0.01 to 5 percent of transdermal absorption penetration enhancers. The polymer hydrogel prepared by the invention has good skin-friendly property and skin permeability, long time for releasing the medicine, good biological adhesiveness with the skin, repeated uncovering and pasting, no residual colloid, and particularly good adhesiveness maintained even if a user sweats during the exercise.
Description
Technical Field
The invention relates to the technical field of polymer hydrogel, in particular to polymer hydrogel with a slow release function and a preparation method thereof.
Background
Because people pay more and more attention to health, frequent sports, muscle strain is inevitable, or muscle needs to be protected before sports, but the traditional products on the market are easy to fall off due to sweating in the process of sports, or are used in combination with protective equipment, so that the use sense is heavy.
Current bandage development is largely around base fabric improvements, including the use of self-adhesive tape, stretch base fabrics, and the like. However, after treatment of a wound, direct contact between the bandage and the skin wound, often with exudates around the wound, and often poor breathability of the bandage, bacterial infection is likely to occur. Brings great pain to the wound and is not beneficial to the healing of the wound. The existing bandage using the hot melt adhesive coating cannot have a substantial transdermal drug delivery function, and the colloid does not have salt resistance, or some hydrogel bandage products have a complex structure due to the defect that hydrogel is easy to penetrate through cloth, are heavy in use feeling, poor in skin adhesion feeling, not light and thin, and are easy to fall off when sweating during sports.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide a polymer hydrogel with a slow release function and a preparation method thereof.
The purpose of the invention is realized by the following technical scheme:
the invention provides a polymer hydrogel with a slow release function, which comprises the following components in percentage by mass:
0.01 to 15 percent of active medicine component, 0.01 to 15 percent of ion inhibitor, 0.01 to 1 percent of cross-linking agent, 0.1 to 10 percent of macromolecular resin, 10 to 35 percent of solvent, 0.1 to 15 percent of skin feel conditioning agent, 10 to 55 percent of deionized water, 0.1 to 3 percent of appearance conditioning agent, 0.01 to 1 percent of cross-linking conditioning agent, 0.01 to 1 percent of preservative and 0.01 to 5 percent of transdermal absorption penetration enhancer.
Preferably, the polymer hydrogel comprises the following components in percentage by mass:
1 to 10 percent of active ingredients, 3 to 10 percent of ion inhibitors, 0.1 to 0.5 percent of cross-linking agents, 5 to 10 percent of macromolecular resins, 20 to 35 percent of solvents, 1 to 5 percent of skin feel conditioning agents, 30 to 55 percent of deionized water, 0.1 to 1 percent of appearance conditioning agents, 0.1 to 1 percent of cross-linking conditioning agents, 0.1 to 0.5 percent of preservatives and 1 to 5 percent of transdermal absorption penetration enhancers.
More preferably, the polymer hydrogel comprises the following components in percentage by mass:
4 to 6 percent of active ingredients, 5 percent of ion inhibitors, 0.1 to 0.2 percent of cross-linking agents, 8 to 9.5 percent of macromolecular resins, 30 to 33 percent of solvents, 0.1 percent of skin feel conditioning agents, 40.9 to 52.04 percent of deionized water, 0.05 to 0.1 percent of appearance conditioning agents, 0.2 percent of cross-linking conditioning agents, 0.1 percent of preservatives and 0.5 percent of transdermal absorption penetration enhancers.
Preferably, the active ingredient comprises any one or more of a pharmaceutical ingredient, a traditional Chinese medicine powder or extract, an amino acid and a plant extract. For example, the pharmaceutical composition can be selected from analgesic components such as glucosamine, capsicum extract, camphor, menthol, methyl salicylate, lidocaine hydrochloride, etc., and can also be selected from anti-inflammatory analgesic components such as aspirin, analgin, acetaminophen, indomethacin, piroxicam, ketorolac, cortisone, hydrocortisone, dexamethasone, glycyrrhetinic acid, felbinac, loxoprofen, etc.; the Chinese medicinal powder or extractive solution can be selected from Borneolum Syntheticum, Aloe, flos Camelliae Japonicae, Olibanum resin, flos Caraganae Sinicae, radix Angelicae sinensis, semen Cassiae, herba Sidae Rhombifoliae, purple coneflower, and juniper fruit; the amino acid can be selected from glycine, serine, L-tryptophan, arginine, ornithine, 5-hydroxytryptophan, L-theanine, and theanine; the plant extract can be selected from plant extracts of sleep-aiding components such as valerian extract, passion flower extract, lemon balm leaf, chamomile extract, lavender extract, chamomile extract, balm extract, sour cherry extract, garlic extract, spearmint extract and the like, and can also be selected from plant extracts with the functions of refreshing and restoring consciousness such as wintergreen oil, angelica dahurica oil, angelica sinensis oil, cinnamon oil, eucalyptus oil, peppermint oil, borneol, patchouli oil and the like.
Preferably, the ionic inhibitor comprises at least one of polyvinylpyrrolidone and a nonionic ionic inhibitor of polyvinyl alcohol.
Preferably, the cross-linking agent is aluminum chlorohydrate or aluminum hydroxide.
Preferably, the polymer resin is at least one of polyacrylic acid and sodium polyacrylate.
Preferably, the solvent comprises at least one of glycerol, propylene glycol, mineral oil, polyoxyethylene sorbitan monooleate.
Preferably, the skin feel modifier is at least one of kaolin and sodium carboxymethyl cellulose;
the appearance regulator is titanium dioxide.
More preferably, the skin feel modifier is kaolin, which is an oil-absorbing inorganic powder that can modify the oil components secreted on the skin during exercise.
Preferably, the crosslinking regulator is at least one of tartaric acid, citric acid, EDTA-2Na, EDTA-4Na, malic acid and lactic acid;
the preservative is at least one of benzalkonium chloride, methyl paraben, propyl paraben and phenoxyethanol;
the transdermal absorption penetration enhancer is at least one of isopropyl myristate, dimethyl sulfoxide and azone.
The invention also provides a preparation method of the polymer hydrogel with the slow release function, which comprises the following steps:
s1, mixing the sodium polyacrylate, the cross-linking agent, the cross-linking regulator and the appearance regulator with the solvent, stirring for 8-15 minutes at normal temperature, and dispersing uniformly to form phase A;
s2, adding the active pharmaceutical ingredients into the solvent to be dissolved completely into a B phase at normal temperature;
s3, stirring the ionic inhibitor, the skin feel regulator, the transdermal absorption enhancer and the preservative for 15-20 minutes at normal temperature to form a mixed solution which is a phase C;
and S4, emulsifying the phase B and the phase C in a homogenizing emulsifying machine, pouring the emulsified liquid into a vacuum stirring kettle, mixing the phase A with the phase B, and stirring to obtain the polymer hydrogel with the slow release function.
Preferably, in step S4, the rotation speed of emulsification is 4000r/min, and the emulsification time is 10-15 minutes; the stirring speed is 40-60r/min, and the stirring time is 10-15 minutes.
The conventional colloid is applied to a human body, the viscosity of the hydrogel is reduced due to sweat secreted by the human body, and the hydrogel prepared by the invention can enhance the adhesion effect under the condition of sweat due to the addition of a certain content of the ion inhibitor.
Compared with the prior art, the invention has the following beneficial effects:
the hydrogel prepared by the invention is prepared by allowing sodium polyacrylate to exist in a hydrophilic matrix in a cross-linked state, embedding active ingredients in a formed polymer skeleton, compounding the colloid with a nonionic aqueous ion inhibitor, and improving the salt resistance of the colloid.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
Example 1
The embodiment provides a polymer hydrogel with a slow release function, which comprises the following components in percentage by mass: 4% lidocaine (active ingredient), 5% polyvinylpyrrolidone (ion inhibitor), 0.1% aluminum glycollate (cross-linking agent), 5% sodium polyacrylate (polymer resin), polyacrylic acid 3% (polymer resin), 24% glycerol (solvent), 5% propylene glycol (solvent), 1% polyoxyethylene sorbitan monooleate (solvent), 0.1% kaolin (skin feel modifier), 0.05% titanium dioxide (appearance modifier), 0.1% tartaric acid (cross-linking modifier), 0.1% EDTA-2Na (cross-linking modifier), 0.1% phenoxyethanol (preservative), 0.5% dimethyl sulfoxide (transdermal absorption enhancer), 51.95% deionized water.
The preparation method of the polymer hydrogel comprises the following steps:
(1) stirring sodium polyacrylate, dihydroxyaluminum glycolate, kaolin, EDTA-2Na, tartaric acid and glycerol at normal temperature for 10 minutes to obtain phase A;
(2) adding lidocaine into propylene glycol and polyoxyethylene sorbitan monooleate, and dissolving at normal temperature to obtain phase B;
(3) and stirring polyvinylpyrrolidone, titanium dioxide, dimethyl sulfoxide and phenoxyethanol in deionized water at normal temperature for 15-20 minutes to form a mixed solution which is a phase C.
(4) Emulsifying the phase B and the phase C in a homogenizing emulsifying machine for 10-15 minutes at the rotation speed of 4000r/min, pouring the mixed liquid into a vacuum stirring kettle, mixing the phase A with the mixed liquid, and stirring for 10-15 minutes at the stirring speed of 40-60r/min to form the hydrogel paste embedding the active pharmaceutical ingredients.
Example 2
The embodiment provides a polymer hydrogel with a slow release function, which comprises the following components in percentage by mass: 5% menthol (active ingredient), 5% polyvinylpyrrolidone (ion inhibitor), 0.1% aluminum glycollate (cross-linking agent), 5.5% sodium polyacrylate (polymer), 3.5% polyacrylic acid (polymer), 23% glycerol (solvent), 7% propylene glycol (solvent), 1% polyoxyethylene sorbitan monooleate (solvent), 0.1% sodium carboxymethylcellulose (skin feel modifier), 0.1% titanium dioxide (appearance modifier), 0.1% tartaric acid (cross-linking modifier), 0.1% EDTA-2Na (cross-linking modifier), 0.1% benzalkonium chloride (preservative), 0.5% isopropyl myristate (transdermal absorption enhancer), 48.9% deionized water.
The preparation method of the polymer hydrogel comprises the following steps:
(1) stirring sodium polyacrylate, aluminium glycollate, sodium carboxymethylcellulose, EDTA-2Na, tartaric acid and glycerol at normal temperature for 10 min to obtain phase A;
(2) adding menthol into propylene glycol and polyoxyethylene sorbitan monooleate, and dissolving at normal temperature to obtain phase B;
(3) stirring polyvinylpyrrolidone, titanium dioxide, isopropyl myristate and phenoxyethanol in deionized water at normal temperature for 15-20 minutes to form a mixed solution as a C phase.
(4) Emulsifying the phase B and the phase C in a homogenizing emulsifying machine for 10-15 minutes at the rotation speed of 4000r/min, pouring the mixed liquid into a vacuum stirring kettle, mixing the phase A with the mixed liquid, and stirring for 10-15 minutes at the stirring speed of 40-60r/min to form the hydrogel paste embedding the active ingredients.
Example 3
The embodiment provides a polymer hydrogel with a slow release function, which comprises the following components in percentage by mass: 5% menthol (active ingredient), 5% polyvinylpyrrolidone (ion inhibitor), 0.2% aluminium hydroxide (cross-linking agent), 3.5% sodium polyacrylate (macromolecule), 6% polyacrylic acid (macromolecule), 25% glycerol (solvent), 7% propylene glycol (solvent), 1% polyoxyethylene sorbitan monooleate (solvent), 0.1% sodium carboxymethylcellulose (skin feel modifier), 0.1% titanium dioxide (appearance modifier), 0.1% tartaric acid (cross-linking modifier), 0.1% EDTA-2Na (cross-linking modifier), 0.1% methyl paraben (preservative), 0.1% propyl paraben (preservative), 0.5% isopropyl myristate (transdermal absorption enhancer), 46.2% deionized water.
The preparation method of the polymer hydrogel comprises the following steps:
(1) stirring sodium polyacrylate, aluminum hydroxide, sodium carboxymethylcellulose, EDTA-2Na, tartaric acid and glycerol at normal temperature for 10 minutes to obtain phase A;
(2) adding menthol into propylene glycol and polyoxyethylene sorbitan monooleate, and dissolving at normal temperature to obtain phase B;
(3) and stirring polyvinylpyrrolidone, titanium dioxide, isopropyl myristate, methyl hydroxybenzoate and propyl hydroxybenzoate in deionized water at normal temperature for 15-20 min to obtain a mixed solution as phase C.
(4) Emulsifying the phase B and the phase C in a homogenizing emulsifying machine for 10-15 minutes at the rotation speed of 4000r/min, pouring the mixed liquid into a vacuum stirring kettle, mixing the phase A with the mixed liquid, and stirring for 10-15 minutes at the stirring speed of 40-60r/min to form the hydrogel paste embedding the active ingredients.
Example 4
The invention provides a polymer hydrogel with a slow release function, which is basically the same as that in example 1 in component composition, and is different from the polymer hydrogel in that: in this example, polyvinyl alcohol was used instead of polyvinylpyrrolidone.
The hydrogels prepared in examples 1-4 above have good skin-friendly and skin-permeable properties, long drug release time, good bio-adhesion to skin, repeated release, no residual gel, and good adhesion even if a user sweats, especially when used during exercise.
Example 5
The invention provides a polymer hydrogel with a slow release function, which is basically the same as that in example 1 in component composition, and is different from the polymer hydrogel in that: in this embodiment, polyvinyl alcohol is used to replace polyvinylpyrrolidone, and the content of polyvinyl alcohol is 3% and the content of deionized water is 53.95%.
Example 6
The invention provides a polymer hydrogel with a slow release function, which is basically the same as that in example 1 in component composition, and is different from the polymer hydrogel in that: in this embodiment, polyvinyl alcohol is used to replace polyvinylpyrrolidone, and the content of polyvinyl alcohol is 8% and the content of deionized water is 48.95%.
Example 7
The invention provides a polymer hydrogel with a slow release function, which is basically the same as that in example 1 in component composition, and is different from the polymer hydrogel in that: in this embodiment, polyvinyl alcohol is used to replace polyvinylpyrrolidone, and the content of polyvinyl alcohol is 10% and the content of deionized water is 46.95%.
Comparative example 1
The comparative example provides a polymer hydrogel with a slow-release function, and the components of the polymer hydrogel are basically the same as those of example 1, except that: in this comparative example, no crosslinker was added and the deionized water content was 52.14%.
The preparation method of the polymer hydrogel is the same as that of example 1.
The prepared colloid has no cross-linking agent, so the cross-linking process is too fast or too slow, the cross-linking degree of the colloid is not uniform, and the coating cannot be carried out.
Comparative example 2
The comparative example provides a polymer hydrogel with a slow-release function, and the components of the polymer hydrogel are basically the same as those of example 1, except that: in this comparative example, no ion inhibitor was added and the deionized water content was 56.95%.
The preparation method of the polymer hydrogel is the same as that of example 1.
Effect verification:
the hydrogel pastes prepared in example 1 and comparative example 2 were coated on an elastic cloth, covered with a release cover layer, cut, and cured to obtain a hydrogel patch. The obtained hydrogel patch is subjected to effect test, and the specific test method and result are as follows:
the gel patches of example 1 and comparative example 2 were cut into 3 strips of 30cm by 2.5cm samples, and about 2 g of artificial sweat was uniformly applied to the surface of each of the hydrogel patches for 2 hours at 25 ± 2 ℃ and 60% RH according to the test method of GB/T2792-:
TABLE 1
From the above test results, comparative example 2 has a significantly reduced adhesion effect under the condition of immersion in artificial sweat, since no ion inhibitor is added.
The gel patches of examples 2-7 were cut into 3 strips of 30cm by 2.5cm samples according to the method described above, and about 2 g of artificial sweat was uniformly applied to the surface of each strip of hydrogel patch and pretreated at 25. + -. 2 ℃ and 60% RH for 2 hours, according to the GB/T2792-:
TABLE 2
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Claims (10)
1. The polymer hydrogel with the slow release function is characterized by comprising the following components in percentage by mass:
0.01 to 15 percent of active ingredients, 0.01 to 15 percent of ion inhibitors, 0.01 to 1 percent of cross-linking agents, 0.1 to 10 percent of macromolecular resin, 10 to 35 percent of solvents, 0.1 to 15 percent of skin feel conditioning agents, 10 to 55 percent of deionized water, 0.1 to 3 percent of appearance conditioning agents, 0.01 to 1 percent of cross-linking conditioning agents, 0.01 to 1 percent of preservatives and 0.01 to 5 percent of transdermal absorption penetration enhancers.
2. The polymer hydrogel with a sustained-release function according to claim 1, wherein the active ingredient comprises any one or more of a pharmaceutical ingredient, a powder or an extract of a traditional Chinese medicine, an amino acid, and a plant extract.
3. The polymer hydrogel with sustained-release function according to claim 1, wherein the ionic inhibitor comprises at least one of polyvinylpyrrolidone and a nonionic ionic inhibitor of polyvinyl alcohol.
4. The polymer hydrogel with a sustained-release function according to claim 1, wherein the crosslinking agent is aluminum glycoxide or aluminum hydroxide.
5. The polymer hydrogel with sustained-release function according to claim 1, wherein the polymer resin is at least one of polyacrylic acid and sodium polyacrylate.
6. The polymer hydrogel having sustained-release function according to claim 1, wherein the solvent comprises at least one of glycerol, propylene glycol, mineral oil, and polyoxyethylene sorbitan monooleate.
7. The polymer hydrogel with a sustained-release function according to claim 1, wherein the skin-feel modifier is at least one of kaolin and sodium carboxymethyl cellulose;
the appearance regulator is titanium dioxide.
8. The polymer hydrogel with sustained-release function according to claim 1, wherein the crosslinking modifier is at least one of tartaric acid, citric acid, EDTA-2Na, EDTA-4Na, malic acid, and lactic acid;
the preservative is at least one of benzalkonium chloride, methyl paraben, propyl paraben and phenoxyethanol;
the transdermal absorption penetration enhancer is at least one of isopropyl myristate, dimethyl sulfoxide and azone.
9. The preparation method of the polymer hydrogel with the slow release function according to claim 1, which is characterized by comprising the following steps:
s1, mixing the sodium polyacrylate, the cross-linking agent, the cross-linking regulator and the appearance regulator with part of the solvent, stirring for 8-15 minutes at normal temperature, and uniformly dispersing to form phase A;
s2, adding the active pharmaceutical ingredients into partial solvent to be dissolved completely into a B phase at normal temperature;
s3, stirring the ionic inhibitor, the skin feel regulator, the transdermal absorption enhancer and the preservative for 15-20 minutes at normal temperature to form a mixed solution which is a phase C;
and S4, emulsifying the phase B and the phase C in a homogenizing emulsifying machine, pouring the emulsified liquid into a vacuum stirring kettle, mixing the phase A into the vacuum stirring kettle, and stirring to obtain the polymer hydrogel with the slow release function.
10. The method for preparing polymer hydrogel with sustained-release function according to claim 9, wherein in step S4, the rotation speed of emulsification is 4000r/min, and the emulsification time is 10-15 minutes; the stirring speed is 40-60r/min, and the stirring time is 10-15 minutes.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110269382.8A CN112807484A (en) | 2021-03-12 | 2021-03-12 | Polymer hydrogel with slow release function and preparation method thereof |
| PCT/CN2022/080351 WO2022188861A1 (en) | 2021-03-12 | 2022-03-11 | Polymer hydrogel with sustained-release function, and preparation method therefor and application thereof |
| US18/033,371 US20230381371A1 (en) | 2021-03-12 | 2022-03-11 | Polymer hydrogel with slow-release function and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110269382.8A CN112807484A (en) | 2021-03-12 | 2021-03-12 | Polymer hydrogel with slow release function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112807484A true CN112807484A (en) | 2021-05-18 |
Family
ID=75863190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110269382.8A Pending CN112807484A (en) | 2021-03-12 | 2021-03-12 | Polymer hydrogel with slow release function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112807484A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022188861A1 (en) * | 2021-03-12 | 2022-09-15 | 上海创始医疗科技(集团)股份有限公司 | Polymer hydrogel with sustained-release function, and preparation method therefor and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857261A (en) * | 2006-03-30 | 2006-11-08 | 华中科技大学 | Aquogel type thiamazole plaster preparation |
| CN105997957A (en) * | 2016-07-08 | 2016-10-12 | 韩春超 | Fucoxanthine hydrogel patch for preventing and treating obesity |
| CN108704162A (en) * | 2018-08-08 | 2018-10-26 | 中国科学院长春应用化学研究所 | A kind of water suction dressing and preparation method thereof |
| WO2019143114A1 (en) * | 2018-01-18 | 2019-07-25 | 대화제약 주식회사 | Hydrogel-patch-type pharmaceutical composition for transdermal administration |
| CN111568885A (en) * | 2020-06-14 | 2020-08-25 | 陕西健吉跃生物科技有限公司 | Hydrogel patch containing nicotinamide and preparation method and application thereof |
-
2021
- 2021-03-12 CN CN202110269382.8A patent/CN112807484A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857261A (en) * | 2006-03-30 | 2006-11-08 | 华中科技大学 | Aquogel type thiamazole plaster preparation |
| CN105997957A (en) * | 2016-07-08 | 2016-10-12 | 韩春超 | Fucoxanthine hydrogel patch for preventing and treating obesity |
| WO2019143114A1 (en) * | 2018-01-18 | 2019-07-25 | 대화제약 주식회사 | Hydrogel-patch-type pharmaceutical composition for transdermal administration |
| CN108704162A (en) * | 2018-08-08 | 2018-10-26 | 中国科学院长春应用化学研究所 | A kind of water suction dressing and preparation method thereof |
| CN111568885A (en) * | 2020-06-14 | 2020-08-25 | 陕西健吉跃生物科技有限公司 | Hydrogel patch containing nicotinamide and preparation method and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022188861A1 (en) * | 2021-03-12 | 2022-09-15 | 上海创始医疗科技(集团)股份有限公司 | Polymer hydrogel with sustained-release function, and preparation method therefor and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5564469B2 (en) | Improved transdermal delivery system for rotigotine administration | |
| KR101015491B1 (en) | Patch | |
| US20040156886A1 (en) | Sheet-like patch agent | |
| CA2362299C (en) | Sheet-form adhesive preparation | |
| JP2003514835A (en) | Methods and compositions for treating scarring | |
| US20110300198A1 (en) | Hydrocolloid - essential oil patches | |
| WO2003092677A1 (en) | Trans-epicutaneous administration form for treating restless leg syndrome | |
| JP4596751B2 (en) | Anti-inflammatory analgesic patch | |
| CN112807484A (en) | Polymer hydrogel with slow release function and preparation method thereof | |
| CN112870427A (en) | Hydrogel elastic patch and preparation method thereof | |
| JPS61275212A (en) | Ketoprofen-containing poultice | |
| KR100614090B1 (en) | Sheet-type packs | |
| JP4575632B2 (en) | Drugs for migraine relief | |
| CN110227102B (en) | Ointment for promoting blood circulation and relieving swelling and preparation method thereof | |
| JPH04234322A (en) | Self-pressure-sensitive matrix system for durable percutaneous release of pyrivedil | |
| WO2022188861A1 (en) | Polymer hydrogel with sustained-release function, and preparation method therefor and application thereof | |
| JP3193161B2 (en) | Transdermal absorption preparation | |
| JPS6112614A (en) | Drug for external use | |
| JPS60260513A (en) | Poultice | |
| JPH09268123A (en) | Cataplasm for local anesthesia | |
| JPH078784B2 (en) | Hydrophilic transdermal preparation | |
| CA2926146A1 (en) | Novel formulation | |
| JPH05310598A (en) | Agent for percutaneous administration | |
| JP4274951B2 (en) | Taping type patch having a support using an irregular cross-section fiber | |
| JP7340140B2 (en) | Water-containing compositions, patches, cosmetics or dermatological medicines comprising the water-containing compositions, and methods for producing these |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210518 |
|
| RJ01 | Rejection of invention patent application after publication |